ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1394

Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study

Bon San Koo1, Subin Hwang1, Ye-Jee Kim2, Soo Min Ahn2 and Wook Jang Seo3, 1Inje University Seoul Paik Hospital, Seoul, South Korea, 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, 3Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), Nonsteroidal antiinflammatory drugs (NSAIDs), Renal, risk factors

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: (1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term NSAID use has been linked to an increased risk of developing chronic kidney disease (CKD). This study aimed to identify the risk factors, including cumulative NSAID dosage, associated with CKD in AS patients using data from the National Health Insurance.

Methods: The incidence of CKD was determined in AS patients diagnosed between May 1, 2016, and December 31, 2019, using Korean national health insurance data. The cumulative NSAID dosage was assessed using the ASAS NSAID Intake Score. The ASAS NSAID Intake Score was categorized into four groups based on the score at 3 months, 6 months, and 1-year intervals: = 0, >0 and ≤33.3, >33.3 and ≤66.6, and >66.6. The hazard ratio was used to evaluate the risk of CKD based on baseline characteristics. A nested case-control analysis was performed to investigate the correlation between the ASAS NSAID Intake Score during 3 months, 6 months, and 1 year before CKD diagnosis and the development of CKD.

Results: Out of the initial 12,000 AS patients, 120 were identified with CKD. The incidence rate of CKD was 4.64 per 10,000 patient-years. Factors significantly associated with CKD included age ≥60 (Ref. age< 30, HR 3.27, 95% CI 1.49 – 7.17), Charlson comorbidity index 1–2 (HR 1.65, 95% CI 1.049 – 2.612) and 3–4 (HR 2.27, 95% CI 1.27 – 4.08), hypertension (HR 2.408, 95% CI 1.595 – 3.634), diabetes mellitus (HR 1.538, 95% CI 1.016 – 2.329), and sulfasalazine (HR 0.682.76, 95% CI 0.47 – 0.99) (Table 1). However, the odds ratios adjusted for comorbidity and medication did not show a correlation between the 3-month, 6-month, and 1-year ASAS NSAID Intake Scores and CKD. A 1-year ASAS NSAID Intake Score > 66.6 was associated with a reduced risk of CKD (OR 0.46, 95% CI 0.22–0.94) (Table 2).

Conclusion: The risk of CKD in AS patients was associated with comorbidities. However, long-term NSAID use may not be associated with an increased risk of CKD.

Supporting image 1

Table 1. Hazard ratio of chronic kidney disease by baseline characteristics

Supporting image 2

Table 2. Odd ratio between cases and matched controls in 3-months, 6-months, and one-year interval


Disclosures: B. Koo: None; S. Hwang: None; Y. Kim: None; S. Ahn: None; W. Seo: None.

To cite this abstract in AMA style:

Koo B, Hwang S, Kim Y, Ahn S, Seo W. Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/comorbidities-not-long-term-use-of-nonsteroidal-anti-inflammatory-drugs-may-be-associated-with-chronic-kidney-disease-in-patients-with-ankylosing-spondylitis-a-nationwide-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comorbidities-not-long-term-use-of-nonsteroidal-anti-inflammatory-drugs-may-be-associated-with-chronic-kidney-disease-in-patients-with-ankylosing-spondylitis-a-nationwide-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology